As a result of several investigations, we have come to realize the important role that virus nucleic acids play in the transference of genetic infectious properties to new generations. The influence of nucleases on those acids is widely known and detailed in elementary biochemestry books.
Research has demonstrated that nucleases restrain the developmentof pathogenic virus preparations. The primary mechanism of such antiviral action, is the destruction of the viral nucleotide bonds, denaturalizing the viruses consequently, destroying the generic information with so, its infectious properties. This action takes place where the viruses lose theur protective protein coat after having entered the living macro-organism's cell. There is the case where nucleases infiltrate the hematoencephalic barrier, they have very low toxicity, they do not interfere with respiration, neighter with arterial blood pressure, nor with the tone of involuntary muscles additionally, they do not have a toxic action over teh central nervous system.
The most important investigation with nucleases was held between 1960 and 1980. These studies revealed their effectiveness in the fight against viral disseases in plants, animals and human beings. It has been proven that RNAse delays the flu virus in tissue and cultures and chicken embryos. The virus looses its activity due to the depolimerization of the viral RNA.
According to the circunstances of the microstructure of the viruses, RNAse is used in diseases caused by viruses that contain ribonucleic acid, such as, viruses of: peritonitis, laryngitis, encephalitis, meningitis, equineencephalitis, enterovirus, as well as viruses that cause liver, ovaric, upper, respiratory, breast and pancreatic cancer, and even the rabies virus.
Enzymatic coadjuvant in certain viral processes
Cancer treatment alternative
Dosage and administration:
It will Vary depending on the severity of the illness and patient's age, from 1 to 5ml, intramuscular application every 12, 24 or 72 hours.
Up to 25 ml dissolved in 250 ml of sodium chloride isotonic solution applied by venoclisis every 12 o 72 hours.
The recommended dosage is from 2ml, twice a week, by intramuscular application to a daily dose of 5 ml for a 60 kg adult, depending on the severity of the ilness.
Ridasa is contraindicated in patients with hypersensitivity to nucleases. Ridasa should not be used during pregnancy.
Presentation: 25 ml. vial.
No. Reg. 0038m81 S.S.A.
(01) 800-8499878 o (55) 57952856